PMID- 10477530
OWN - NLM
STAT- MEDLINE
DCOM- 20000113
LR  - 20211203
IS  - 1524-4539 (Electronic)
IS  - 0009-7322 (Linking)
VI  - 100
IP  - 10
DP  - 1999 Sep 7
TI  - Comparison of candesartan, enalapril, and their combination in congestive heart 
      failure: randomized evaluation of strategies for left ventricular dysfunction 
      (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators.
PG  - 1056-64
AB  - BACKGROUND: We investigated the effects of candesartan (an angiotensin II 
      antagonist) alone, enalapril alone, and their combination on exercise tolerance, 
      ventricular function, quality of life (QOL), neurohormone levels, and 
      tolerability in congestive heart failure (CHF). METHODS AND RESULTS: Seven 
      hundred sixty-eight patients in New York Heart Association functional class 
      (NYHA-FC) II to IV with ejection fraction (EF) <0.40 and a 6-minute walk distance 
      (6MWD) <500 m received either candesartan (4, 8, or 16 mg), candesartan (4 or 8 
      mg) plus 20 mg of enalapril, or 20 mg of enalapril for 43 weeks. There were no 
      differences among groups with regard to 6MWD, NYHA-FC, or QOL. EF increased 
      (P=NS) more with candesartan-plus-enalapril therapy (0.025+/-0.004) than with 
      candesartan alone (0.015+/-0.004) or enalapril alone(0.015+/-0.005). 
      End-diastolic (EDV) and end-systolic (ESV) volumes increased less with 
      combination therapy (EDV 8+/-4 mL; ESV 1+/-4 mL; P<0.01) than with candesartan 
      alone (EDV 27+/-4 mL; ESV 18+/-3 mL) or enalapril alone (EDV 23+/-7 mL; ESV 
      14+/-6 mL). Blood pressure decreased with combination therapy (6+/-1/4+/-1 mm Hg) 
      compared with candesartan or enalapril alone (P<0.05). Aldosterone decreased 
      (P<0.05) with combination therapy (23.2+/-5.3 pg/mL) at 17 but not 43 weeks 
      compared with candesartan (0.7+/-7.8 pg/mL) or enalapril (-0.8+/-11. 3 pg/mL). 
      Brain natriuretic peptide decreased with combination therapy (5.8+/-2.7 pmol/L; 
      P<0.01) compared with candesartan (4. 4+/-3.8 pmol/L) and enalapril alone 
      (4.0+/-5.0 pmol/L). CONCLUSIONS: Candesartan alone was as effective, safe, and 
      tolerable as enalapril. The combination of candesartan and enalapril was more 
      beneficial for preventing left ventricular remodeling than either candesartan or 
      enalapril alone.
FAU - McKelvie, R S
AU  - McKelvie RS
AD  - Hamilton Health Sciences Corporation-General Division, and McMaster University, 
      Hamilton, Ontario, Canada. mckelrob@hamcivhos.on.ca
FAU - Yusuf, S
AU  - Yusuf S
FAU - Pericak, D
AU  - Pericak D
FAU - Avezum, A
AU  - Avezum A
FAU - Burns, R J
AU  - Burns RJ
FAU - Probstfield, J
AU  - Probstfield J
FAU - Tsuyuki, R T
AU  - Tsuyuki RT
FAU - White, M
AU  - White M
FAU - Rouleau, J
AU  - Rouleau J
FAU - Latini, R
AU  - Latini R
FAU - Maggioni, A
AU  - Maggioni A
FAU - Young, J
AU  - Young J
FAU - Pogue, J
AU  - Pogue J
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Circulation
JT  - Circulation
JID - 0147763
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Drug Combinations)
RN  - 0 (Hormones)
RN  - 0 (Tetrazoles)
RN  - 69PN84IO1A (Enalapril)
RN  - AYI8EX34EU (Creatinine)
RN  - RWP5GA015D (Potassium)
RN  - S8Q36MD2XX (candesartan)
SB  - IM
CIN - Circulation. 1999 Sep 7;100(10):1032-4. PMID: 10477526
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Benzimidazoles/*therapeutic use
MH  - Biphenyl Compounds
MH  - Blood Pressure/drug effects
MH  - Creatinine/blood
MH  - Drug Combinations
MH  - Enalapril/*therapeutic use
MH  - Female
MH  - Heart Failure/*drug therapy/physiopathology
MH  - Heart Rate/drug effects
MH  - Hormones/blood
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Pilot Projects
MH  - Potassium/blood
MH  - Tetrazoles/*therapeutic use
MH  - Ventricular Dysfunction, Left/drug therapy/physiopathology
MH  - Ventricular Function
EDAT- 1999/09/08 00:00
MHDA- 1999/09/08 00:01
CRDT- 1999/09/08 00:00
PHST- 1999/09/08 00:00 [pubmed]
PHST- 1999/09/08 00:01 [medline]
PHST- 1999/09/08 00:00 [entrez]
AID - 10.1161/01.cir.100.10.1056 [doi]
PST - ppublish
SO  - Circulation. 1999 Sep 7;100(10):1056-64. doi: 10.1161/01.cir.100.10.1056.